The earnings call presented a mixed outlook. Positive aspects included strong growth in the software and life sciences segments, robust cash flow, and successful innovation launches. However, these were counterbalanced by significant challenges in the diagnostics business, particularly in China due to DRG policy changes, leading to a lowered full-year guidance. Additionally, academic and government customer revenue showed continued weakness.

Company Guidance -

Q3 2025

In the Q2 2025 earnings call, Revvity provided updated guidance, reflecting both challenges and achievements. The company reported a robust cash flow generation with $115 million in free cash flow and a free cash flow conversion rate of 90% year-to-date. Despite challenges in the Chinese market due to the diagnosis-related groups (DRG) policy, which impacted the Diagnostics segment, Revvity achieved 3% organic growth, led by a 4% growth in the Life Sciences business and a remarkable 30% growth in the Signals software franchise. The company anticipates full-year organic growth of 2% to 4%, slightly down from prior expectations, and adjusted EPS is expected to be $4.85 to $4.95. Revvity also continued its aggressive share repurchase strategy, repurchasing nearly $300 million worth of stock in the second quarter, totaling $450 million in buybacks for the first half of the year.

Strong Software Growth

The Signals software franchise grew approximately 30% organically, with a new record for orders in a single quarter, indicating robust future performance.

Life Sciences Business Growth

The Life Sciences segment grew 4% organically, driven by mid-single-digit growth with pharma and biotech customers.

Solid Cash Flow and Share Repurchase

Revvity generated $115 million of free cash flow and repurchased nearly $300 million worth of stock in the second quarter, totaling $450 million for the first half of the year.

Reproductive Health Business Outlook

The reproductive health business is expected to grow in the high single digits in the fourth quarter due to the ramp-up of sequencing volumes from a Genomics England contract.

Innovation in Diagnostics

Launch of IDS i20 platform, a breakthrough in specialty testing automation, which is expected to significantly contribute to future growth.

ESG Recognition

Revvity's continuous improvement in sustainability, governance, and social priorities was recognized by MSCI with an AAA ESG rating.

Revvity (RVTY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RVTY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	1.14 / -	1.28	―	―	―
Jun 29, 2025	2025 (Q2)	1.15 / 1.18	1.22	-3.28% (-0.04)	―	―
Apr 28, 2025	2025 (Q1)	0.95 / 1.01	0.98	3.06% (+0.03)
Jan 31, 2025	2024 (Q4)	1.37 / 1.42	1.25	13.60% (+0.17)
Nov 04, 2024	2024 (Q3)	1.13 / 1.28	1.18	8.47% (+0.10)
Jul 29, 2024	2024 (Q2)	1.12 / 1.22	1.21	0.83% (+0.01)
Apr 29, 2024	2024 (Q1)	0.94 / 0.98	1.01	-2.97% (-0.03)
Feb 01, 2024	2023 (Q4)	1.17 / 1.25	1.7	-26.47% (-0.45)
Oct 30, 2023	2023 (Q3)	1.19 / 1.18	1.51	-21.85% (-0.33)
Aug 01, 2023	2023 (Q2)	1.19 / 1.21	2.32	-47.84% (-1.11)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RVTY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 28, 2025	$94.22	$94.99	+0.82%
Jan 31, 2025	$126.65	$125.94	-0.56%
Nov 04, 2024	$120.79	$124.56	+3.12%
Jul 29, 2024	$114.84	$125.26	+9.07%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.